UCB's Bimekizumab Shows Durable HS Control in 3-Year Data, Bolstering Long-Term Market Position

Event summary

  • UCB presented data at the 2026 AAD Annual Meeting showing 86.1% of HS patients treated with BIMZELX experienced no acute exacerbations over three years.
  • Post-hoc analyses indicated improved outcomes with earlier treatment and lower disease severity.
  • Efficacy improvements were observed across HS patient subgroups, including age, BMI, and disease duration.
  • The data are derived from post-hoc analyses of the BE HEARD trials, involving 367 patients at Week 148.

The big picture

UCB's BIMZELX is establishing itself as a key player in the treatment of HS, a niche market with significant unmet need and a growing patient population. The durable symptom control demonstrated in this three-year data strengthens BIMZELX's value proposition and reinforces UCB's commitment to long-term evidence generation. This data supports the trend towards earlier intervention in HS, highlighting the importance of timely diagnosis and treatment to improve patient outcomes.

What we're watching

Market Adoption
The long-term data will likely influence physician prescribing habits and patient demand for BIMZELX, particularly given the high unmet need in HS and the burden of flares.
Competitive Landscape
Competitors in the HS space will scrutinize these results and may accelerate their own development programs or marketing efforts to capture market share.
Regulatory Scrutiny
Given the post-hoc nature of the analyses, regulatory agencies may require further investigation or validation of these findings to support expanded indications or labeling claims.